These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 15133781)

  • 1. Early onset of hyperkalemia in patients treated with low molecular weight heparin: a prospective study.
    Koren-Michowitz M; Avni B; Michowitz Y; Moravski G; Efrati S; Golik A
    Pharmacoepidemiol Drug Saf; 2004 May; 13(5):299-302. PubMed ID: 15133781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heparin-induced hyperkalemia in chronic hemodialysis patients: comparison of low molecular weight and unfractionated heparin.
    Hottelart C; Achard JM; Moriniere P; Zoghbi F; Dieval J; Fournier A
    Artif Organs; 1998 Jul; 22(7):614-7. PubMed ID: 9684701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum concentration of potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate, losartan potassium or candesartan cilexetil.
    Saito M; Takada M; Hirooka K; Isobe F; Yasumura Y
    J Clin Pharm Ther; 2005 Dec; 30(6):603-10. PubMed ID: 16336294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variations of serum potassium level and risk of hyperkalemia in inpatients receiving low-molecular-weight heparin.
    Gheno G; Cinetto L; Savarino C; Vellar S; Carraro M; Randon M
    Eur J Clin Pharmacol; 2003 Sep; 59(5-6):373-7. PubMed ID: 12851802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Laboratory monitoring of potassium and creatinine in ambulatory patients receiving angiotensin converting enzyme inhibitors and angiotensin receptor blockers.
    Raebel MA; McClure DL; Simon SR; Chan KA; Feldstein A; Andrade SE; Lafata JE; Roblin D; Davis RL; Gunter MJ; Platt R
    Pharmacoepidemiol Drug Saf; 2007 Jan; 16(1):55-64. PubMed ID: 16470693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No impact of hyperkalaemia with renin-angiotensin system blockades in maintenance haemodialysis patients.
    Han SW; Won YW; Yi JH; Kim HJ
    Nephrol Dial Transplant; 2007 Apr; 22(4):1150-5. PubMed ID: 17255126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin.
    Montalescot G; Collet JP; Tanguy ML; Ankri A; Payot L; Dumaine R; Choussat R; Beygui F; Gallois V; Thomas D
    Circulation; 2004 Jul; 110(4):392-8. PubMed ID: 15249498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure.
    Tamirisa KP; Aaronson KD; Koelling TM
    Am Heart J; 2004 Dec; 148(6):971-8. PubMed ID: 15632880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How useful is determination of anti-factor Xa activity to guide bridging therapy with enoxaparin? A pilot study.
    Hammerstingl C; Omran H; Tripp C; Poetzsch B
    Thromb Haemost; 2009 Feb; 101(2):325-32. PubMed ID: 19190817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low molecular weight heparin in the treatment of venous and arterial thromboses in the premature infant.
    Michaels LA; Gurian M; Hegyi T; Drachtman RA
    Pediatrics; 2004 Sep; 114(3):703-7. PubMed ID: 15342842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Electrolyte and acid-base balance disorders in advanced chronic kidney disease].
    Alcázar Arroyo R
    Nefrologia; 2008; 28 Suppl 3():87-93. PubMed ID: 19018744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversal of glucose-induced hyperkalemia by sodium restriction in "normaldosteronemic" diabetes mellitus.
    Radó JP
    Endokrinologie; 1981 Dec; 78(2-3):244-52. PubMed ID: 7037374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of low-molecular-weight heparin to bridge therapy in obese patients and in patients with renal dysfunction.
    George-Phillips KL; Bungard TJ
    Pharmacotherapy; 2006 Oct; 26(10):1479-90. PubMed ID: 16999658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heparin resistance and increased platelet activation in coronary surgery patients treated with enoxaparin preoperatively.
    Pleym H; Videm V; Wahba A; Asberg A; Amundsen T; Bjella L; Dale O; Stenseth R
    Eur J Cardiothorac Surg; 2006 Jun; 29(6):933-40. PubMed ID: 16675258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantification of the risk and predictors of hyperkalemia in patients with left ventricular dysfunction: a retrospective analysis of the Studies of Left Ventricular Dysfunction (SOLVD) trials.
    de Denus S; Tardif JC; White M; Bourassa MG; Racine N; Levesque S; Ducharme A
    Am Heart J; 2006 Oct; 152(4):705-12. PubMed ID: 16996842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized comparative study of using enoxaparin instead of unfractionated heparin in the intervention treatment of coronary heart disease.
    Chen JL; Chen J; Qiao SB; Guo YL; Wu YJ; Dai J; Yuan JQ; Qin XW; Yang YJ; Gao RL
    Chin Med J (Engl); 2006 Mar; 119(5):355-9. PubMed ID: 16542576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
    Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T
    Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Laboratory evaluation of potassium and creatinine among ambulatory patients prescribed spironolactone: are we monitoring for hyperkalemia?
    Raebel MA; McClure DL; Chan KA; Simon SR; Feldstein AC; Lafata JE; Andrade SE; Gunter MJ; Nelson WW; Roblin D; Platt R
    Ann Pharmacother; 2007 Feb; 41(2):193-200. PubMed ID: 17284506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of sodium intake on plasma potassium and renin angiotensin aldosterone system in conscious dogs.
    Kjolby MJ; Kompanowska-Jezierska E; Wamberg S; Bie P
    Acta Physiol Scand; 2005 Jul; 184(3):225-34. PubMed ID: 15954990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increasingly restrictive definitions of hyperkalemia outcomes in a database study: effect on incidence estimates.
    Raebel MA; Ross C; Cheetham C; Petersen H; Saylor G; Smith DH; Wright LA; Roblin DW; Xu S
    Pharmacoepidemiol Drug Saf; 2010 Jan; 19(1):19-25. PubMed ID: 19937982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.